Product logins

Find logins to all Clarivate products below.


Location Location Location: How Shifting Procedural Site of Service Affects Competitive Strategy in the Orthopedic Device Industry

Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often elective. This differentiating factor is one of many contributing drivers to the noticeable changing site of service for some orthopedic procedures; many orthopedic procedures are moving away from the traditional hospital setting and towards ambulatory surgical centers. As a key stakeholder, medical device firms have to come to grips with this changing landscape and demonstrate the strategic willingness to capitalize on this trend. In spite of the presence of many significant obstacles, including but not limited to challenges to reimbursement in the ASC setting, medical device manufacturers looking to benefit from this site of service shift must adapt their existing portfolios, make an effort to understand the reimbursement and demographic landscape relevant to ASCs, and adjust their pricing and marketing strategies to target ASCs. In so doing, as ASCs assume a more pivotal role in orthopedic care over time, orthopedic medical device companies taking these steps can better ready themselves to effectively compete in the increasingly entrenched orthopedic device market.

Related Market Assessment Reports

Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…